We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AMRX market cap is 1.82B. The company's latest EPS is USD -0.3776 and P/E is -15.55.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 629.65M | 659.19M | 701.78M | 702.47M | 730.52M |
| Operating Income | 14.19M | -10.65M | 95.47M | 87.78M | 75.79M |
| Net Income | -98.65M | -91.64M | 5.99M | -156k | -31.08M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.99B | 2.09B | 2.22B | 2.41B | 2.79B |
| Operating Income | 91.16M | 158.08M | -96.84M | 204.37M | 248.4M |
| Net Income | 91.06M | 10.62M | -129.99M | -83.99M | -116.89M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.47B | 3.46B | 3.51B | 3.46B | 3.5B |
| Total Liabilities | 3.41B | 3.47B | 3.51B | 3.49B | 3.55B |
| Total Equity | 20.01M | -63.63M | -57.49M | -93.57M | -109.51M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 4.01B | 3.94B | 3.8B | 3.47B | 3.5B |
| Total Liabilities | 3.65B | 3.56B | 3.59B | 3.41B | 3.55B |
| Total Equity | 344.93M | 366.97M | 183.98M | 20.01M | -109.51M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 345.58M | -4.41M | 35.25M | 177.02M | 295.1M |
| Investing | -69.19M | -19.76M | -26.23M | -46.94M | -63M |
| Financing | -212.57M | -23.16M | -58.24M | -150.59M | -211.79M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 379M | 241.82M | 65.1M | 345.58M | 295.1M |
| Investing | -317.55M | -194.18M | -174.31M | -69.19M | -63M |
| Financing | 131.81M | -138.12M | -106.62M | -212.57M | -211.79M |
| Market Cap | 1.82B |
| Price to Earnings Ratio | -15.55 |
| Price to Sales Ratio | 0.65 |
| Price to Cash Ratio | 16.44 |
| Price to Book Ratio | -40.8 |
| Dividend Yield | - |
| Shares Outstanding | 309.54M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.29 (4.87%) |
| Company Name | Amneal Pharmaceuticals Holding Co |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.amneal.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
